Tacrolimus Market to Surpass US$ 9,380.2 Million by 2030

Global Tacrolimus Market, by Product Type (Tacrolimus Capsules and Tablets, Tacrolimus Ointment, Tacrolimus Injection, and Tacrolimus Granules), by Application (Immunosuppression, Dermatitis, and Others), by End User (Organ Transplant Centers, Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 6,485.3 Million in 2022 and is expected to exhibit a CAGR of 4.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increased product launches by the key players in the market is expected to drive the market growth over the forecast period. For instance, in March 2019, Astellas Pharma Inc., a multinational pharmaceutical company based in Japan, announced the launch of PROGRAF granules (tacrolimus for oral suspension) in the U.S. as prescription medicine. PROGRAF is used in combination with other immunosuppressant to help prevent organ rejection in people who had a liver, heart, or kidney transplant. Children who have trouble swallowing capsules can be given PROGRAF granules.

Global Tacrolimus Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

The COVID-19 pandemic had a negative impact on the tacrolimus market due to the increased risk of getting affected by the COVID-19 infection following organ transplantation. Solid organ transplant recipients may be at greater risk for COVID-19 because they are immunosuppressed and are less likely to cause effective immune responses to vaccination.

Moreover, the decreased rates of organ transplantations during the pandemic had a negative impact on the tacrolimus market. For instance, according to an article published by the journal The Transplantation Society, in April 2022, the COVID-19 pandemic had a major global impact on solid organ transplantation (SOT). An estimated 16% global decrease in transplant activity occurred over the course of 2020, most markedly impacting living donor programs and kidney transplants.

Browse 35 Market Data Tables and 34 Figures spread through 190 Pages and in-depth TOC on “Global Tacrolimus Market”-  Forecast to 2030, Global Tacrolimus Market, by Product Type (Tacrolimus Capsules and Tablets, Tacrolimus Ointment, Tacrolimus Injection, and Tacrolimus Granules), by Application (Immunosuppression, Dermatitis, and Others), by End User (Organ Transplant Centers, Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Tacrolimus Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/tacrolimus-market-2298

Moreover, increasing establishment of new organ transplant centers is expected to drive the segment growth over the forecast period. For instance, in November 2021, Sahyadri Super Speciality Hospital, a full-fledged tertiary care multispecialty hospital, started a taluka level organ transplant center at Karad, India. The organ transplant center will conduct liver, pancreas, and kidney transplants.

Key Takeaways of the Global Tacrolimus Market:

• The global tacrolimus market is expected to exhibit a CAGR of 4.7% during the forecast period, owing to the increasing research activities by scientists on tacrolimus and its appropriate use in immunosuppression and other applications. For instance, according to an article published in the journal Frontiers Media S.A., a leading open access publisher in pharmacology, on November 2021, scientists of the Rajiv Gandhi Centre for Biotechnology (RGCB), located in Kerala, India, formulated a method to predict the optimal dose of an immunosuppressant drug, tacrolimus, given to kidney transplant patients. This dose prediction study was focused on tacrolimus, an immunosuppressant drug given to a kidney, heart, or liver transplant patient to lower the body’s immunity, thereby reducing the chances of organ rejection.
• Among end users, the hospital segment is estimated to hold a dominant position in the global tacrolimus market over the forecast period, owing to the increasing approvals to hospitals by authorities to begin organ transplant facilities in the hospitals. For instance, in March 2022, King George’s Medical University, a medical school, hospital, and medical university located in Lucknow, India, received permission from the Directorate of Medical Education and Training, an organization that aims to improve education in the field of Medical Science, to begin with a kidney transplant program at the hospital.
• Among regions, North America is estimated to account for the largest market share in the global tacrolimus market over the forecast period, owing to the increasing product launches by the key players in the region. For instance, in December 2020, Biocon, an innovation-led global biopharmaceutical company, announced the launch of Tacrolimus capsules in the U.S. Tacrolimus is a calcineurin inhibitor, an immunosuppressant used in the treatment of organ transplant patients that reduces the body’s ability to reject a transplanted organ.
• Major players operating in the global tacrolimus market include Novartis AG, Mylan N.V., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Abbott, Senju Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, and Vibcare Pharma Pvt. Ltd.